Previous studies suggested ER-α as an important therapeutic target for the management of BC pathogenesis (Ariazi et al., 2006; García-Becerra et al., 2012; Giacinti et al., 2006; Hanstein et al., 2004; Kang et al., 2012b; Renoir, Marsaud & Lazennec, 2013; Wik et al., 2013). This evidence concerns the gene ESR1 and breast cancer.